Trial document



drksid header

  DRKS00015842

Trial Description

start of 1:1-Block title

Title

Maximum Bite Force in Patients with Spinal Muscular Atrophy during the First Year of Nusinersen Therapy – A Pilot Study

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

We measure bite force in patients with spinal muscular atrophy. These patients receive a therapy with nusinersen. We hope to evaluate the effect of the therapy on the bulbar function based on the bite force measurements.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Spinal muscular atrophy (SMA) is characterized by progressive spinal and bulbar muscle weakness and atrophy caused by the degeneration of alpha-motoneurons. The recent approval of the antisense oligonucleotide nusinersen highlights the need for reliable clinical tools to evaluate motor function in patients with SMA. This study’s aim is to test if maximum bite force measurement is suitable to quantify changes of altered bulbar function during nusinersen therapy.
We want to include patients at an advanced state of SMA. In patients in an advanced stage, the maximum bite force could be a quantitative measure of the bulbar function and thus an alternative to conventional motor scales, which require residual mobility of the extremities and of the head. The aim of this study is to perform isometric bite force measurements in SMA patients to show possible changes in maximum bite force indicating changes in bulbar function. A piezoelectric force sensor registers the maximum bite force in the posterior region recorded by the CEBO-MSA64 software. Relative bite force changes in different treatment phases are analyzed.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00015842
  •   2019/07/30
  •   [---]*
  •   yes
  •   Approved
  •   19-1137_1, Ethik-Kommission der Medizinischen Fakultät der Universität zu Köln
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   G12.1 -  Other inherited spinal muscular atrophy
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   We measure bite force in patients with spinal muscular atrophy during Nusinersen therapy (Spinraza, Biogen).
  •   We measure bite force in patients with spinal muscular atrophy before and during Nusinersen therapy (Spinraza, Biogen).
  •   We measure bite force in patients with spinal muscular atrophy without Nusinersen therapy.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Non-randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Control group receives no treatment
  •   Other
  •   Other
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Relative changes in maximum bite force. Measured with piezoelectric transducers. Maximum bite force is repeatedly measured over the course of one year.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Relative change of maximum bite force.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Planned
  •   2019/10/01
  •   50
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   50   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Patients with spinal muscular atrophy type I or II.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

SMA type III

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Poliklinik für Kieferothopädie, Uniklinik Köln
    • Kerpener Str. 32
    • 50931  Köln
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • Poliklinik für Neurologie
    • Mr.  Dr.  Gilbert  Wunderlich 
    • Kerpener Str. 62
    • 50937  Köln
    • Germany
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Poliklinik für Kieferorthopädie, Uniklinik Köln
    • Ms.  Dr.  Teresa  Kruse 
    • Kerpener Str. 32
    • 50931  Köln
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Poliklinik für Kieferorthopädie, Uniklinik Köln
    • Ms.  Dr.  Teresa  Kruse 
    • Kerpener Str. 32
    • 50931  Köln
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Poliklinik für Kieferorthopädie, Uniklinik Köln
    • Ms.  Dr.  Teresa  Kruse 
    • Kerpener Str. 32
    • 50931  Köln
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting planned
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.